Cargando…

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma

Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danno, Tetsuya, Iwata, Shohei, Niimi, Fusako, Honda, Sachi, Okada, Haruka, Azuma, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270715/ https://www.ncbi.nlm.nih.gov/pubmed/34306793 http://dx.doi.org/10.1155/2021/9936330

Ejemplares similares

Cerebral metastasis during remission after immunotherapy for metastatic urothelial carcinoma: A case report
por: Iwata, Shohei, et al.
Publicado: (2021)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
por: Funajima, Keisuke, et al.
Publicado: (2023)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
por: Mullally, W. J., et al.
Publicado: (2022)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
por: Pacholczak-Madej, Renata, et al.
Publicado: (2022)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report
por: Fuu, Takayoshi, et al.
Publicado: (2022)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
por: Reuss, Joshua E., et al.
Publicado: (2016)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
por: Guercio, Brendan John, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
por: Minor, David R., et al.
Publicado: (2022)

Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report
por: Yasuoka, Shotaro, et al.
Publicado: (2018)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2020)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma
por: Iwaki, Takuya, et al.
Publicado: (2020)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Savarapu, Pramod, et al.
Publicado: (2021)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report
por: Delombaerde, Danielle, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lt432thb1rfc9ma3uheec8qqc7